Project Grant R01DA061116
Award Date
7/1/25
Completion Date
3/31/30
Dollars Obligated
$553K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award of $2,331,737 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a comprehensive study to investigate the impact of methamphetamine (MA) use on HIV persistence, immune dysfunction, and clinical outcomes among people living with HIV (PWH) on antiretroviral therapy (ART). The study will leverage three unique cohorts to perform the first-in-human investigations directly quantifying MA concentrations in...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $804,728 to the Regents of the University of California at Riverside to investigate the role of methamphetamine and cysteinyl leukotrienes in HIV persistence. The research aims to: 1) determine how methamphetamine engages the cysteinyl leukotriene-cysteinyl leukotriene receptor 1 axis to increase HIV infection of CD4+ T-cells and...
The National Institute on Drug Abuse (NIDA) awarded Myosin Therapeutics Inc. a $2,916,991 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to support a Phase 1B clinical trial of their novel therapeutic agent MT-110 for the reduction of methamphetamine use disorder (MUD). The trial will recruit up to 44 patients to test 5 dose levels of MT-110 and determine the safety, tolerability, and pharmacokinetics of this one-time administration medication. Secondary endpoints...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $634,048 to The University of Kentucky Research Foundation to conduct a human laboratory study evaluating the efficacy of the drug troriluzole as a treatment for methamphetamine use disorder (MUD), both alone and in cases of co-occurring MUD and opioid use disorder (OUD). The study aims to translate previous preclinical findings on...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $237,750 to Temple University to conduct research on the effects of xylazine on methamphetamine-induced behavioral alterations in rats. The key objectives are to evaluate how xylazine impacts methamphetamine self-administration, reinforcing efficacy, seeking behaviors, and associated molecular biomarkers in the nucleus accumbens. This...
This $3,287,052 Cooperative Agreement (Award ID: UG3DA061709) was awarded on May 15, 2025 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports Virogenomics Biodevelopment, Inc., a woman-owned small business, in conducting IND-enabling studies and Phase I clinical trials to advance DRHQ, a novel immunotherapeutic compound targeting CD74 receptors as a potential treatment for methamphetamine use disorder. Key activities...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $1,481,760 to Emory University to study how methamphetamine (MA) use impacts immune dysfunction in people living with HIV (PWH) on antiretroviral therapy (ART). The 5-year award will leverage existing longitudinal blood samples and collect new blood and cerebrospinal fluid samples to investigate a multi-step process by which MA promotes...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $240,108 to Drexel University to elucidate the corticolimbic circuit and neuroimmune mechanisms underlying the dysregulation of reward-seeking behavior in the comorbid condition of HIV and cocaine use disorder (CUD). The research aims to use circuit-specific optogenetics and chemogenetics in mouse models to understand how HIV infection,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $454,251 to The Trustees of the University of Pennsylvania to develop a novel "released markers of activity" (RMAs) blood-based monitoring system for long-term tracking of neural circuit activity and opioid receptor gene expression changes in mice exposed to opioids. The goal is to better understand the molecular and functional...
The National Institute on Drug Abuse (NIDA) awarded a $135,765 project grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Washington to investigate the role of corticotropin-releasing factor (CRF) in modulating accumbal dopamine and producing escalation of drug intake. The research aims to 1) test the necessity of CRF receptor 1 in the nucleus accumbens (NAc) for the escalation of drug taking, and 2) examine the modulation of phasic dopamine response...